Status:
COMPLETED
Peptide-based Immunization for Colon- and and Pancreas-carcinoma
Lead Sponsor:
CENTOGENE GmbH Rostock
Conditions:
Colon Neoplasm
Colon Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
An international, multicenter study to identify tumor molecular particularities and neoepitopes among participants with colorectal and pancreatic tumors undergoing surgery.
Detailed Description
Colorectal and pancreatic cancers are among the most common causes of cancer-related death over the world. Standard of care treatment for colon and pancreas cancer is stage dependent and includes surg...
Eligibility Criteria
Inclusion
- Informed consent is obtained from the participant
- Patients with pancreas or colorectal carcinoma undergoing surgery
- The participant is older than 18 years old
Exclusion
- Inability to provide informed consent
- The patient is not suffering from pancreas or colo-rectal carcinoma
- Patient has a condition contradicting surgery
- The participant is younger than 18 years old
- Previously enrolled in the study
Key Trial Info
Start Date :
April 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03871790
Start Date
April 1 2019
End Date
August 31 2022
Last Update
February 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Teaching Hospital UOL Cancer Center
Lahore, Pakistan